Prostate cancer is the most common cancer among middle-aged men and its early diagnosis will be of great importance in the treatment process. Prostate cancer easily metastasizes to the bones and can cause painful conditions for the patient.
For targeted treatment of prostate cancer, it must be well diagnosed firstly. Ga-68-PSMA radiopharmaceutical with FDA approval is used to diagnose prostate cancer. After being injected, the radiopharmaceutical goes to the tumor site and binds to the antigens on the surface of the prostate cancer cell. Being gamma emitter due to presence of the gallium-68 radioisotope, it can be used for detection of metastatic prostate cancer by positron emission tomography.